Helping projects
change the future
APPLY NOW

News

Primer Capital Master Class at the BiotechWorld 2019

22 February 2019

Primer Capital COO, Elizaveta Rozhestvenskaya to speak on Survival of a Scientific Idea at the Starting Up a Biotech From Scratch master class during the "Biotechnology: state of the art and perspectives. Life Sciences" International Congress.

Primer Capital Master Class at the BiotechWorld 2019

Primer Capital COO, Elizaveta Rozhestvenskaya to speak on Survival of a Scientific Idea at the Starting Up a Biotech From Scratch master class during the "Biotechnology: state of the art and perspectives. Life Sciences" International Congress.

 

Botkin.AI Cancer Diagnostic Solution is now available on Microsoft Azure

12 February 2019

Primer Capital’s portfolio unit, Botkin.AI is available on Microsoft Azure Marketplace. Developed by Intellogic Company Botkin.AI has become the first solution for AI analysis of the CT scans in the world which is available on Microsoft Azure Marketplace.

Botkin.AI Cancer Diagnostic Solution is now available on Microsoft Azure

Primer Capital’s portfolio unit, Botkin.AI is available on Microsoft Azure Marketplace. Developed by Intellogic Company Botkin.AI has become the first solution for AI analysis of the CT scans in the world which is available on Microsoft Azure Marketplace.

 

Botkin.AI Pilot Project Successfully Detected Lung Cancer

6 February 2019

Primer Capital’s portfolio unit, Botkin.AI had its pilot project’s The Diagnostic Scans Screening Using AI Technologies results finalized at Skolkovo on January 29th.

Botkin.AI Pilot Project Successfully Detected Lung Cancer

Primer Capital’s portfolio unit, Botkin.AI had its pilot project’s The Diagnostic Scans Screening Using AI Technologies results finalized at Skolkovo on January 29th.
 

Russian Venture Market Outlook 2019

18 January 2019

Primer Capital COO Elizaveta Rozhdestvenskaya & investment analyst Sofya Yartseva shared their expert opinion on the Russian Venture Market Outlook 2019  for  Invest-Forsight Business Magazine.

Russian Venture Market Outlook 2019

Primer Capital COO Elizaveta Rozhdestvenskaya & investment analyst Sofya Yartseva shared their expert opinion on the Russian Venture Market Outlook 2019  for  Invest-Forsight Business Magazine.
 

Primer Capital Ranked As One Of The Leading Venture Funds In Russia

27 December 2018

According to the RBC annual rating Primer Capital made it to the top 5 most active venture funds in Russia.

Primer Capital Ranked As One Of The Leading Venture Funds In Russia

According to the RBC annual rating Primer Capital made it to the top 5 most active venture funds in Russia.
 

Primer Capital’s portfolio company Bendit received the Best Technology Parade Presentation award at the ICI meeting 2018

21 December 2018

Primer Capital’s portfolio company Bendit(Israel) received the Best Technology Parade Presentation award at the ICI (Innovations in Cardiovascular Interventions) Meeting 2018 in Tel Aviv, Israel.

Primer Capital’s portfolio company Bendit received the Best Technology Parade Presentation award at the ICI meeting 2018

Primer Capital’s portfolio company Bendit(Israel) received the Best Technology Parade Presentation award at the ICI (Innovations in Cardiovascular Interventions) Meeting 2018 in Tel Aviv, Israel.
 

A day with a medicine venture capitalist

11 December 2018

Primer Capital CEO Maria Belousova and COO Elizaveta Rozhdestvenskaya for  Invest-Forsight Business Magazine.

A day with a medicine venture capitalist

Primer Capital CEO Maria Belousova and COO Elizaveta Rozhdestvenskaya for  Invest-Forsight Business Magazine.
 

Drug for Ischemic Stroke Raises $15.3 million

25 October 2018

Primer Capital’s portfolio company, Acticor Biotech (France), has closed a $15.3 million Series B round of financing from European and Asian investors. This funding will enable the company to finance the first Phase II of its antithrombotic drug for the acute phase of ischemic stroke.

Drug for Ischemic Stroke Raises $15.3 million

Primer Capital’s portfolio company, Acticor Biotech (France), has closed a $15.3 million Series B round of financing from European and Asian investors. This funding will enable the company to finance the first Phase II of its antithrombotic drug for the acute phase of ischemic stroke.
 

Primer Capital Is the Best Venture Capitalist 2018

17 October 2018

Primer Capital was awarded the «Best investment at an early stage» within the contest «National VC Awards» for investing into Botkin.AI – the clinical decision support system based on artificial intelligence technologies.

Primer Capital Is the Best Venture Capitalist 2018

Primer Capital was awarded the «Best investment at an early stage» within the contest «National VC Awards» for investing into Botkin.AI – the clinical decision support system based on artificial intelligence technologies.
 

Primer Capital Invests in the Development of Molecular Bacteriotherapy of Atopic Dermatitis

8 October 2018

Primer Capital Venture Fund invested $200K in California-based company MatriSys Bioscience. It is developing MSB-01, a commensal strain of bacteria S. hominis, that selectively kills an aggressive strain of Staphylococcus aureus that colonizes the skin of patients with atopic dermatitis (eczema). Moreover, MBS-01 helps to restore normal skin microbiome.

Primer Capital Invests in the Development of Molecular Bacteriotherapy of Atopic Dermatitis

Primer Capital Venture Fund invested $200K in California-based company MatriSys Bioscience. It is developing MSB-01, a commensal strain of bacteria S. hominis, that selectively kills an aggressive strain of Staphylococcus aureus that colonizes the skin of patients with atopic dermatitis (eczema). Moreover, MBS-01 helps to restore normal skin microbiome.

Записи 1 - 10 of 31
First | Prev. | 1 2 3 4 | Next | Last